Aldeyra Therapeutics announces positive early results in trial of dry eye disease treatment [MarketWatch]
Aldeyra Therapeutics, Inc. (ALDX)
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aldeyra.com/investor-relations
Company Research
Source: MarketWatch
Aldeyra Therapeutics announces positive early results in trial of dry eye disease treatment Aldeyra Therapeutics Inc. shares ALDX, -6.14% rose more than 13% in premarket trade Tuesday before surrendering their gains, after the biotech reported positive results in the first part of a late-stage trial of a treatment for dry eye disease. The Lexington, Mass.-based company said the Phase 3 Renew trial of topical ocular reproxalap in patients with dry eye disease involved 422 patients in the first part of the trial. "To our knowledge, reproxalap is the first topical dry eye disease drug to demonstrate statistically significant ocular dryness symptom improvement relative to vehicle as soon as one week after initiation of treatment, and thus has the potential to be first-line therapy," Chief Executive Todd C. Brady said in a statement. The primary endpoint of the first part of the trial was to confirm dosing, endpoints and sample size for Renew part 2. Dry eye disease is a common disorder
Show less
Read more
Impact Snapshot
Event Time:
ALDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALDX alerts
High impacting Aldeyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALDX
News
- Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development DayBusiness Wire
- Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024Business Wire
- Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why [Yahoo! Finance]Yahoo! Finance
- Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $10.00 price target on the stock.MarketBeat
ALDX
Earnings
- 8/3/23 - Beat
ALDX
Sec Filings
- 4/25/24 - Form 8-K
- 4/25/24 - Form EFFECT
- 4/22/24 - Form ARS
- ALDX's page on the SEC website